ADP-ribosylation is integral to a diverse range of cellular processes such as DNA repair, chromatin regulation and RNA processing. However, proteome-wide investigation of its cellular functions has been limited due to numerous technical challenges including the complexity of the poly(ADP-ribose) (PAR) chains, low abundance of the modification and lack of sensitive enrichment methods. To facilitate livecell profiling of ADP-ribosylated proteins, we show that 2-alkyne-adenosine (2YnAd) is metabolically incorporated in mammalian cells and enables fluorescent detection and robust affinity enrichment of the modified proteins. We then present an integrated chemical biology approach that involves simultaneous metabolic incorporation of 2YnAd and the previously reported 6-alkyne-adenosine (6YnAd) in live cells followed by click chemistry with a capture reagent to facilitate highly sensitive and comprehensive enrichment of the modified proteins. By combining this dual metabolic labelling strategy with the tandem mass tag (TMT) isobaric mass spectrometry, we have quantified the responses of thousands of endogenous proteins to clinical PARP inhibitors Olaparib and Rucaparib. Our study provides insight into the wider scope of PARP targets and will help to advance further characterisation of their functional roles.
Introduction
Protein ADP-ribosylation is a post-translational modification (PTM) where members of a family of enzymes known as ADP-ribosyltransferases (or PARPs) covalently link ADP-ribose moieties derived from NAD + to the side chains of several possible amino acid residues (glutamate, aspartate, arginine, lysine, cysteine, serine) on target proteins. This PTM exists either as a monomer (mono-ADP-ribosylation), consisting of a single ADP-ribose moiety on the target residue, or as a polymer (poly-ADP-ribosylation) where a branched polymeric chain of ADP-ribose units originates from the target residue. Of the 17 PARPs encoded in the human genome, PARPs 1, 2 and 3 are known to have important roles in DNA regulation, particularly in the base excision repair pathway 1 . Consequently, PARP inhibitors have been developed as cancer therapeutics to exploit the concept of synthetic lethality in patients with germline mutations in BRCA1 or BRCA2 genes 2 . Beyond the established roles of these nuclear PARPs in DNA damage response, the broad cellular functions for the majority of the other members of the PARP family remain elusive primarily due to the lack of analytical techniques for the large-scale profiling of intracellular ADP-ribosylation.
Mass spectrometry (MS) proteomics studies of ADP-ribosylation in particular have been limited due to numerous technical challenges. These include low specificity and/or affinity when using recombinant macro domains 3, 4 , cis-diol binding boronate beads 5 , antibodies 6 or adapted phosphoproteome enrichment strategies 7 to enrich for this low abundance PTM against complex cellular backgrounds. Additionally, most methods reported to date require a priori knockdown of poly-ADP-ribose glycohydrolase (PARG) activity to sufficiently increase the baseline level of poly-ADP-ribosylation for MS detection, which is not ideal since PARG knockdown is known to induce physiological changes in cells 8 . A further limitation of many previous studies is that they have been performed under stress induction, which activates PARP1 and thus potentially masks the underlying activities of the other PARP enzymes 3, 4, 5, 6, 7 .
Results

2-alkyne adenosine (2YnAd) treatment results in labelling of ADP-ribosylated proteins
We treated MDA-MB-231 breast cancer cells with equal concentrations of 2YnAd and 6YnAd in parallel. The cells were then lysed and the whole-cell proteome was clicked with a trifunctional capture reagent Azido-TAMRA-Biotin (Suppl. Fig. 1 ) and resolved on SDS-PAGE.
In-gel fluorescence scans revealed qualitatively similar protein labelling profiles for both 2YnAd and 6YnAd treatments (Fig. 1a,b) . Western blot analysis of the labelling reactions using anti-pan-ADP-ribose antibody 11 following affinity enrichment of the labelled proteins on NeutrAvidin-Agarose resin confirmed significant enrichment of ADP-ribosylated proteins in both 2YnAd and 6YnAd live cell incorporations relative to the input control ( Fig. 1c,d ).
2YnAd provides greater coverage of ADP-ribosylated targets than 6YnAd
After establishing the use of the 2YnAd for live cell labelling of ADP-ribosylated proteins, we performed a proteomic comparison of the labelling between 2YnAd and 6YnAd using the highly sensitive tandem mass tags (TMT)-based isobaric tagging for quantitative mass spectrometry 12 . Using the MDA-MB-231 breast cancer cell line as a model system, we first developed a workflow ( Fig. 2 ) that involves the following sequential steps: (i) parallel metabolic incorporation of 2YnAd and 6YnAd, (ii) bioorthogonal tagging of the ADP-ribosylated proteome using copper (I) catalysed azide-alkyne cycloaddition (CuAAC) click reaction, (iii) affinity enrichment of the labelled proteome using the robust biotin-NeutrAvidin pull-down system, (iv) TMT6plex isobaric labelling and (v) liquid chromatography tandem mass spectrometry (LC-MS/MS) analysis.
Our chemical proteomics workflow for profiling intracellular ADP-ribosylation events identified over 1600 protein targets (Supplementary Dataset File 1, in which proteins previously reported in ADPriboDB 13 are highlighted in bold), representing a significant improvement in proteomic coverage compared to other published studies despite requiring less protein input (500 µg total protein input before affinity enrichment per condition). Importantly, statistical analysis of the replicate data sets using LIMMA 14 revealed that specific subsets of protein targets were preferentially labelled with either 2YnAd or 6YnAd treatment ( Fig. 3 , Suppl. Fig. 2 ), despite the overall qualitative similarity in the labelling observed in the in-gel fluorescence scans. The 2YnAd was found to be preferentially incorporated, labelling more ADP-ribosylated protein targets than the 6YnAd. Additionally, analysis of the biological pathways of these targets (Suppl. Fig. 3 , Supplementary Dataset File 2) specifically revealed a 2YnAd enrichment for proteins involved in proteasome regulation, including several 26S proteasomal subunits.
Dual metabolic labelling using both 2YnAd and 6YnAd elucidates the quantitative response of thousands of ADP-ribosylated proteins to clinical PARP inhibitors
We rationalised that the observed quantitative differences in protein targets labelled by 2YnAd and 6YnAd could be exploited for more comprehensive profiling of the cellular ADP-ribosylome by simultaneously treating cells with both compounds and combining this dual metabolic labelling approach with our quantitative proteomics workflow. Additionally, as several PARP inhibitors have recently emerged as promising cancer therapeutics, we decided to evaluate the dual metabolic labelling strategy for comprehensively and quantitatively profiling global changes to the cellular ADP-ribosylome upon PARP inhibitor treatment ( Fig. 4 ). We treated MDA-MB-231 cells with equimolar concentrations of 2YnAd and 6YnAd to investigate differential labelling of protein ADP-ribosylation for five different concentrations (0, 0.2, 1, 5, 
Discussion
Functionalised full-length NAD + analogues have recently emerged as promising tools for fluorescence-based visualisation of ADP-ribosylation in cell-lysates 11, 16, 17, 18 and in cells 19, 20 .
Due to the lack of cell-permeability of the full-length NAD + analogues, intracellular labelling was performed by transient permeabilisation of the cell membrane using Triton X-100 surfactant. Although permeabilisation of cell membrane using the surfactant is a powerful approach for imaging applications, successful adaptation of the method to large-scale mass spectrometry (MS) proteomics studies of ADP-ribosylation has not been demonstrated to date.
Nevertheless, a chemical genetic discovery method using clickable full-length NAD + analogues has recently enabled selective enrichment and MS profiling of ADP-ribosylated proteins, although the lack of cell permeability of the NAD + analogues has restricted these studies to cell lysates 11 . In a recent advancement in the field, Howard Hang and co-workers reported a chemical biology approach for live cell labelling of ADP-ribosylated proteins using a terminal alkyne functionalised, cell-permeable, NAD + -precursor compound, 6-alkyne adenosine (6YnAd) 10 . Although successful labelling of a few hundred ADP-ribosylated proteins was demonstrated using the 6YnAd, previous studies have shown that the corresponding full-length clickable NAD + cofactor (6-alkyne-NAD) is a weaker substrate of PARP1 than endogenous NAD +16 . This raised the question as to whether the placement of the alkyne group on the NAD + cofactor analogue affects binding and utilisation by the different endogenous PARP enzymes.
We aimed to further develop the metabolic labelling strategy using clickable NAD + precursors, as this approach has the unique advantage of labelling of the ADP-ribosylome directly in the native cellular environment. Since 2-alkyne adenosine (2YnAd), the metabolic precursor for the corresponding full-length clickable NAD + analogue 2-alkyne-NAD + , was also reported to efficiently label the poly(A) tails of mRNA transcripts in live cells 21 similar to the 6YnAd, and recent studies have demonstrated that PARP enzymes are more tolerant to substitutions in this position on NAD +19,20 , we investigated if 2YnAd can also be used for the metabolic labelling of ADP-ribosylome. Our results ( Fig.1) showed for the first time that 2YnAd is also useful for the in-cell labelling of ADP-ribosylated proteins similar to the 6YnAd probe.
As the Western-blot analysis of the labelling by 2YnAd and 6YnAd probes under identical labelling conditions revealed stronger preference for the 2YnAd (Fig. 1d ), we decided to apply quantitative proteomics using the highly sensitive TMT isobaric tagging to conduct a head-tohead comparison between of the labelling of protein targets by the two probes. The TMT labelling strategy offers sample multiplexing and importantly the isobaric nature of the tag results in the pooling of peptide signal across all experimental conditions, which increases the sensitivity in detecting lower abundance ADP-ribosylated proteins relative to any non-specific background. Statistical analysis of our TMTsixplex datasets using LIMMA revealed that the 2YnAd was preferentially incorporated, producing more ADP-ribosylated proteins than the 6YnAd probe and suggests the possibility that the endogenous PARP enzymes elicit a differential structural preference for the two NAD + cofactor analogues.
Interestingly, biological pathway analysis of the identified targets revealed enrichment of several proteins involved in proteasome regulation specifically among the 2YnAd targets, including several 26S proteasomal subunits. 26S proteasomal activity has been previously reported to be promoted by ADP-ribosylation 22 . Similarly, a co-operative interaction between the proteasome subunit PSMD14 and BRCA1 has been implicated in cellular responses to DNA double strand breaks 23 , a niche where nuclear PARPs are known to have key functional roles. It has also been suggested that the negatively charged PARylation may serve as a recognition site for the E3 ubiquitin protein ligases, which facilitates subsequent degradation of the protein in the 26S proteasome 24 . However, the precise biological function of ADPribosylation in proteasome regulation remains unknown.
Our dual metabolic labelling approach involving simultaneous treatment of cells with equimolar concentrations of 2YnAd and 6YnAd probes and its combination with the TMT10plex quantitative proteomics resulted in the largest candidate experimental dataset of cellular ADPribosylome with over 2300 significant proteins. The superior sensitivity of our proteomics technology enabled the systematic profiling of the cellular ADP-ribosylome in an unbiased manner. As an example application, we utilised this methodology to elucidate the first direct and quantitative comparison between the intracellular response in ADP-ribosylation to two clinical PARP inhibitors, Olaparib and Rucaparib. Our findings are in agreement with the recent reports that indicate pivotal functional roles of PARylation in mRNA splicing and modulation of RNAs 25, 26, 27, 28, 29 . This finding is further supported by a recent CRISPR screen that identified several high-confidence mRNA splicing factors, including DDX46 and SRSF11 (lower left quadrant in Figure 4A ) which resulted in increased sensitivity to the PARP inhibitor Olaparib across several cell lines when mutated 30 .
In summary, we presented a quantitative chemical proteomics approach that combines metabolic labelling using clickable adenosine analogues with TMT isobaric MS to measure ADP-ribosylation in live cells without reduction in PARG activity. We showed that 2YnAd outperforms the previously reported 6YnAd in the metabolic labelling of MDA-MB-231 breast cancer cell line. We demonstrated that our method robustly profiled several thousands of intracellular protein targets, and yielded the largest quantitative proteomics data set measuring the ADP-ribosylome reported to date. The increased sensitivity is the result of the unique combination of the dual metabolic labelling enabled by the clickable NAD + precursors, robust pull-down of modified proteins using NeutrAvidin-Biotin interaction, and the pooling effect resulting from utilising TMT isobaric tagging to multiplex experimental conditions. A head-tohead comparison between two clinical PARP inhibitors revealed a correlative response, which further highlights the sensitivity and robustness of this chemical proteomics platform for studying ADP-ribosylation in live cells. We envision this enabling chemical proteomics technology will transform our ability to systematically characterise the intracellular functions ADP-ribosylation in fundamental and disease biology, including cancer research, bacterial and viral infections and autoimmune diseases. In addition, the approach will be instrumental in determining differences in the targets of established PARP inhibitors and the effects of an emerging range of novel compounds designed to be selective for particular PARP enzymes 31 . LIMMA linear model design. Both cofactor preference and inhibitor treatment datasets were analysed using LIMMA method. The linear methods for each of these datasets were designed separately and described below.
2YnAD/6YnAD
The normalised intensities are assumed to be modelled by the following effects in a format We used the following encoding for the effects.
1. Cofactor effect (i.e. the main measured effect). Encoded by +1 in reporters corresponding to 2YnAd and -1 in reporters corresponding to 6YnAd (e.g. sum-toone encoding). Positive coefficients to this factor therefore indicate 2YnAd preference, and negative values indicate 6YnAd preference.
log(concentration) effect: encoded as log values of the concentrations in mM.
Effect is assumed to be the same for both cofactors. Higher values indicate stronger response.
3. Replicate: 1-of-K encoding (minus one redundant term absorbed in intercept). This term accounts for technical-replicate associated bias in protein intensities.
The complete design matrix is available as Supplementary Table 1 . This way values below than zero correspond to decrease in intensity upon inhibition.
Replicate bias: This term accounts for technical-replicate associated bias in protein
intensities. This was encoded with one-in-K encoding with one redundant term absorbed to intercept.
The complete design matrix is available in Supplementary Table 2 .
LIMMA processing and statistical testing. We have used a similar procedure to the one described by Kammers et al 33 . The linear models were encoded as described above. LIMMA analysis was run with the trend parameter set to TRUE (commonly referred to as LIMMA-trend method). After the model has been fit, we have performed statistical testing on the effect coefficients in the model using the equations provided by Kammers et al. Specifically, we have tested the null hypothesis that cofactor effect coefficient is zero in 2YnAd/6YnAd dataset, and the null hypotheses that inhibitor preference effect and inhibition effect coefficients are not zero (separately) in inhibitor treatment dataset. The p values were adjusted with Benjamini-Hochberg method. Any adjusted p values below 0.01 were deemed significant and annotated in the plots and output. In order to generate debiased plots, we have subtracted the values for bias coefficients (e.g. replicate bias and intercept) from the normalised log2 intensities.
Pathway enrichment analysis. Biological pathway enrichment analysis was performed against Reactome database 34 using the R packages ReactomePA 35 and clusterProfiler 36 using the default settings, showing the most descriptive categories with the "by=rowPercentage" parameter set.
Data Availability
The tandem mass spectrometry datasets generated during the current study are available via the PRIDE database (project accession: PXD011631). All of the data analysed during this study are included in this published article (and its Supplementary Information files).
A pending patent application for the utilisation of the dual metabolic labelling using 2YnAd and 6YnAd for identification of intracellular ADP-ribosylation has been filed (Application number: 1810697.1). 
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